scPharmaceuticals Inc

SCPH

$5.49

Closing

▲3.39%

1D

▼-12.44%

YTD

SCPH

BBG00J24RT22

Market cap

$274.66M

52 week high

$7.55

52 week low

$3.25

Volume

144,342

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$274.66M

Analysts' Rating

BUY

Price Target (Mean)

19.17

Total Analysts

6

P/E

Operating Margin

-179.18%

Beta

0.13

Revenue Growth

391.70%

52 week high

$7.55

52 week low

$3.25

Div. Yield

%

EPS Growth

22.22

Company Profile

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.